TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04772339

Intervention type: OTHER
Intervention: Heel-Rise Test
Description: The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.

Intervention type: OTHER
Intervention: Paper Grip Test (PGT)
Description: In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
Study: NCT05005715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
Study: NCT05487027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goldilocks work principle
Description: Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers.
Study: NCT06001021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychopharmacological Intervention
Description: Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychopharmacological Intervention
Description: Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Couple Therapy
Description: CBCT intervention from a trained psychologist in CBT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Couple Therapy
Description: CBCT intervention from a trained psychologist in CBT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of Psychopharmacological Intervention and CBCT
Description: Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
Study: NCT06719999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B4HT Mediterranean Lunch box
Description: lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)
Study: NCT05696886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol with pethidine
Description: Group B got Tramadol with pethidine in the period between January 2022 and December 2022
Study: NCT06160947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical Care
Description: In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
Study: NCT06001021

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and No Intervention
Description: Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
Study: NCT06062394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Penn Med Healthy Heart Program
Description: Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
Study: NCT05555134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
Study: NCT06160947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Medical Care + Chiropractic Care
Description: Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
Study: NCT05638594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 320mg, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg first dose, then 6 mg/kg，q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg first dose, then 6 mg/kg，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 125mg , qd，d1-21, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg，qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 840 mg first dose, then 420 mg, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Description: Every 4 weeks for 5 cycles, premenopausal patients only
Study: NCT06388538

Intervention type: OTHER
Intervention: Conservative treatment (non-operative treatment)
Description: Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)

Intervention type: OTHER
Intervention: Surgical treatment (operative treatment)
Description: Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above
Study: NCT04112862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodiumlactate
Description: intravenous sodiumlactate 600mmol/L
Study: NCT05663749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000mg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 50mg for 8 weeks
Study: NCT05405621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8009 for Injection
Description: BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
Study: NCT04551248

Intervention type: BIOLOGICAL
Intervention: 10 or 13-valent pneumococcal conjugate vaccine
Description: a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.

Intervention type: BIOLOGICAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Single 0.5-mL dose administered intramuscularly or subcutaneously only.

Intervention type: BIOLOGICAL
Intervention: Influenza vaccine
Description: One dose of trivalent influenza vaccine in flu seasons.
Study: NCT06109766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships
Description: Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships
Description: Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting.
Study: NCT06127719

Intervention type: OTHER
Intervention: questionnaires
Description: before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
Study: NCT04253002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robinson's Culturally Adapted Coping with Stress Course (A-CWS)
Description: Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control Condition
Description: Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
Study: NCT06719999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B4HT Mediterranean Lunch box
Description: lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B4HT Mediterranean Lunch box
Description: lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)
Study: NCT06720558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo probiotic
Description: Three-week consumption of placebo probiotic capsules passed off as being actual probiotics

Intervention type: OTHER
Group type: OTHER
Intervention: Open-Label Placebo probiotic
Description: Participants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.

Intervention type: OTHER
Group type: OTHER
Intervention: Control-no treatment
Description: For the first three weeks, the Control group will not be exposed to any intervention.
Study: NCT06721364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide prevention treatment
Description: Intervention I:RAAHI RAAHI is a suicide literacy module that is specially designed to provide individuals with essential knowledge and skills by equipping them with tools to navigate the complexities of mental health and suicide prevention. This module aims to empower people to recognize signs of suicidal ideation, engage in empathetic communication through open discussion, combat stigma, and connect individuals in crisis with appropriate support and resources. The duration of the module will be of three hours.~Intervention II: safeTALK The \&#34;safeTalk\&#34; program is a psychoeducational initiative designed for suicide prevention among adolescents, consisting of a 4-hour workshop that incorporates presentations, videos, discussions, and questions.The workshop is designed according to the standard practices of safeTALK, to assist participants in (a) identifying warning signs of suicide; (b) Avoiding frequent impulses to overlook, dismiss, or avoid discussions about suicide.
Study: NCT06721520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (Botox )
Description: Patients randomized for intrapyloric Botox injection will undergo the following standard procedure: 100 units of Botox are dissolved in 10 mL normal saline. After identifying the pylorus, the 10 mL of Botox solution is injected intramuscularly at the anterior pyloric ring in 2 separate areas and in 1 area on each side of the pyloric ring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyloromyotomy
Description: Patients randomized for pyloromyotomy will undergo standard pyloromyotomy as follows: after identifying the pylorus, a 2-cm longitudinal incision is made with Metzenbaum or Mayo scissors on the anterior pylorus, centered on the pyloric ring. The incision extends through the serosa and muscular layers to expose the submucosa and mucosa, which is left intact. The cut muscle is spread apart until the submucosa bulges up to the level of the cut serosa. Care is taken to avoid perforation, and the surgeon confirms no mucosal perforation at the end of the procedure. If a perforation is encountered, it will be repaired primarily.
Study: NCT06719960

Intervention type: DRUG
Intervention: Dexmedetomidine group
Description: To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the dexmedetomidine group, in addition to propofol infusion at the same doses, dexmedetomidine 0.5 μg/kg-1 loading dose was administered within 10 minutes and then continued as infusion at a dose of 0.2-0.7 μg/kg/h.

Intervention type: DRUG
Intervention: Propofol group
Description: To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the propofol group, propofol loading dose: 0.2-0.5mg/kg, maintenance infusion dose: 0.5-4mg/kg/h was continued.
Study: NCT06719739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens implantation
Description: Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular lens implantation
Description: Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.
Study: NCT06719947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS
Description: 10 sessions of anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) with a defined electrical current intensity over the cortical representation zone of the left diaphragmatic motor cortex
Study: NCT06089265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: Active ketohexokinase inhibitor
Study: NCT06719947

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated HD-tDCS
Description: 10 sessions of sham anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) over the cortical representation zone of the left diaphragmatic motor cortex. The device will provide a 30-second ramp and then maintain a minimal, non-effective continuous current
Study: NCT01997268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 4 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC401B 6 capsules
Study: NCT04692324

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of CSF samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT06452043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PARC program
Description: Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
Study: NCT04692324

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies